CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt

BACKGROUND: Cardiovascular diseases (CVDs) are considered a leading cause of death worldwide. Allelic variation in the CYP2C19 gene leads to a dysfunctional enzyme, and patients with this loss-of-function allele will have an impaired clopidogrel metabolism, which eventually results in major adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Shawky, Ahmed, Sabit, Hussein, Nazih, Mahmoud, Baraka, Khalid, El-Zawahry, Mokhtar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272067/
https://www.ncbi.nlm.nih.gov/pubmed/37202608
http://dx.doi.org/10.1007/s44197-023-00113-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272067/
https://www.ncbi.nlm.nih.gov/pubmed/37202608
http://dx.doi.org/10.1007/s44197-023-00113-4

Ejemplares similares